Streetwise Biotechnology / Pharmaceuticals Articles


Biotech Releases 'Unequivocally Positive' Topline NASH Study Results

Research Report
  ()
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm. read more >
News Update

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

  ()
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. read more >

Biotech Consolidates Shares in Preparation for NASDAQ Listing

Research Report
  ()
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer. read more >

Coverage Initiated on Developer of Women's Reproductive Health Products

Research Report
  ()
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. read more >

Biotech Announces Encouraging HIV Vaccine Results

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics. read more >

Shovelnose Delivers Gold to Westhaven

Contributed Opinion
  ()
Bob Moriarty of 321 Gold profiles a company that holds a large land position in the "most unexplored gold belt in British Columbia." read more >
Management Q&A: View from the Top

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

Managment Q&A: View from the Top
  ()
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. read more >

Biotech's Launch of Pain Product Shows Encouraging Early Metrics

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset. read more >

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'

Research Report
  ()
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. read more >

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

  ()
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

  ()
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. read more >

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. read more >
Showing Results: 1 to 13 of 13

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe